Daniel Anderson, MD
Hematology & Oncology · Saint Paul, MNNPI 1710949920
Payments from drug & device makers
Across 529 payments — averaging $13,844 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2.4M
- Merck$2.4M
- Amgen$532K
- Pfizer$488K
- Takeda Pharmaceuticals U.S.A., Inc.$447K
- Bristol Myers Squibb$393K
- plus $720K from 12 others
Across 8 payments — averaging $917.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$7K
What the payments were for
- Consulting fees$3,50072%
- Speaking & faculty fees$1,27026%
- Food & beverage$451%
- Education$311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $2,379,754 |
| Merck | 237 | $2,364,790 |
| Amgen | 3 | $531,727 |
| Pfizer | 47 | $487,953 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $446,527 |
| Bristol Myers Squibb | 12 | $392,532 |
| Seagen Inc. | 45 | $225,268 |
| Ipsen Bioscience Inc. | 29 | $144,866 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84,121 |
| Genmab A/s | 19 | $72,468 |
| AstraZeneca | 28 | $63,732 |
| Puma Biotechnology, Inc. | 17 | $58,090 |
| Incyte Corporation | 18 | $46,615 |
| Genentech, Inc. | 6 | $24,696 |
| Astrazeneca UK Limited | 1 | $446 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $20 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$1,270
How this compares
$7,323,640 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 53 | $712,603 |
| CalquenceAcalabrutinib Maleate | 29 | $433,259 |
| ImbruvicaIbrutinib | 16 | $253,700 |
| TasignaNilotinib Hcl | 12 | $234,866 |
| Lenalidomide | 22 | $197,586 |
| EliquisApixaban | 53 | $33,177 |
| XareltoRivaroxaban | 12 | $15,203 |
| OxycontinOxycodone Hcl | 13 | $13,707 |
| Abiraterone Acetate | 12 | $9,512 |
| Anastrozole | 137 | $2,793 |
| Tamoxifen Citrate | 42 | $1,252 |
| Dexamethasone | 44 | $973 |
| Letrozole | 36 | $906 |
| Prochlorperazine Maleate | 31 | $630 |
| Oxycodone Hcl | 89 | $613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $63,732 | $433,25929 claims |
| NovartisTasigna | $2,379,754 | $234,86612 claims |
| PfizerEliquis | $487,953 | $33,17753 claims |
| Lilly USA, LLCOlanzapine | $20 | $6821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Other hematology & oncology in Saint Paul
- Yan JiSaint Paul$6.3M
- Charlene FaresSaint Paul$2.2M
- Kurt DemelSaint Paul$307K
- Sara TorgersonSaint Paul$170K
- Shilpa GuptaMinneapolis$16.3M
- Yucai WangRochester$8.2M
- Timothy LarsonMinneapolis$7.2M
- Manish PatelBloomington$6.2M
- Samith KochuparambilMinneapolis$3.3M
- Thomas AmatrudaFridley$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.